Literature DB >> 31850586

Editorial: moving towards the appropriate use of proton pump inhibitors.

Jacob E Kurlander1,2,3, Joel H Rubenstein1,2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31850586      PMCID： PMC7314283          DOI： 10.1111/apt.15564

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN： 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  9 in total

1.  Selecting the Appropriate Patients for Proton Pump Inhibitor Discontinuation: A Teachable Moment.

Authors:  Kevin D Platt; Sameer D Saini; Jacob E Kurlander
Journal:  JAMA Intern Med       Date:  2019-09-01       Impact factor: 21.873

2.  The Right Idea for the Wrong Patient: Results of a National Survey on Stopping PPIs.

Authors:  Jacob E Kurlander; Mark Kolbe; James M Scheiman; Arlene Weissman; John D Piette; Joel H Rubenstein; Akbar K Waljee; Sameer D Saini
Journal:  Clin Gastroenterol Hepatol       Date:  2017-04-06       Impact factor: 11.382

3.  Patients' Perceptions of Proton Pump Inhibitor Risks and Attempts at Discontinuation: A National Survey.

Authors:  Jacob E Kurlander; Jennifer K Kennedy; Joel H Rubenstein; Caroline R Richardson; Sarah L Krein; Raymond De Vries; Sameer D Saini
Journal:  Am J Gastroenterol       Date:  2019-02       Impact factor: 10.864

Review 4.  Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies.

Authors:  Stephanie Medlock; Saeid Eslami; Marjan Askari; Zhila Taherzadeh; Dedan Opondo; Sophia E de Rooij; Ameen Abu-Hanna
Journal:  Clin Gastroenterol Hepatol       Date:  2013-06-21       Impact factor: 11.382

5.  Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting.

Authors:  Joel J Heidelbaugh; Kathleen L Goldberg; John M Inadomi
Journal:  Am J Manag Care       Date:  2010-09       Impact factor: 2.229

6.  Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Paul Moayyedi; John W Eikelboom; Jackie Bosch; Stuart J Connolly; Leanne Dyal; Olga Shestakovska; Darryl Leong; Sonia S Anand; Stefan Störk; Kelly R H Branch; Deepak L Bhatt; Peter B Verhamme; Martin O'Donnell; Aldo P Maggioni; Eva M Lonn; Leopoldo S Piegas; Georg Ertl; Matyas Keltai; Nancy Cook Bruns; Eva Muehlhofer; Gilles R Dagenais; Jae-Hyung Kim; Masatsugu Hori; P Gabriel Steg; Robert G Hart; Rafael Diaz; Marco Alings; Petr Widimsky; Alvaro Avezum; Jeffrey Probstfield; Jun Zhu; Yan Liang; Patricio Lopez-Jaramillo; Ajay Kakkar; Alexander N Parkhomenko; Lars Ryden; Nana Pogosova; Antonio Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek Guzik; Dragos Vinereanu; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; Kaj Metsarinne; Keith A A Fox; Salim Yusuf
Journal:  Gastroenterology       Date:  2019-05-02       Impact factor: 22.682

7.  Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.

Authors:  Linxin Li; Olivia C Geraghty; Ziyah Mehta; Peter M Rothwell
Journal:  Lancet       Date:  2017-06-13       Impact factor: 79.321

8.  Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.

Authors:  Benjamin Scally; Jonathan R Emberson; Enti Spata; Christina Reith; Kelly Davies; Heather Halls; Lisa Holland; Kate Wilson; Neeraj Bhala; Christopher Hawkey; Marc Hochberg; Richard Hunt; Loren Laine; Angel Lanas; Carlo Patrono; Colin Baigent
Journal:  Lancet Gastroenterol Hepatol       Date:  2018-02-21

9.  Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.

Authors:  Janusz A Z Jankowski; John de Caestecker; Sharon B Love; Gavin Reilly; Peter Watson; Scott Sanders; Yeng Ang; Danielle Morris; Pradeep Bhandari; Claire Brooks; Stephen Attwood; Rebecca Harrison; Hugh Barr; Paul Moayyedi
Journal:  Lancet       Date:  2018-07-26       Impact factor: 202.731
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.